Citigroup reissued their buy rating on shares of AstraZeneca (LON:AZN) in a research note issued to investors on Wednesday morning, Digital Look reports. Citigroup currently has a £100 ($130.67) target price on the biopharmaceutical company’s stock, up from their previous target price of GBX 7,000 ($91.47).
A number of other research firms have also issued reports on AZN. Societe Generale reaffirmed a buy rating on shares of AstraZeneca in a report on Tuesday, September 10th. Barclays raised their target price on AstraZeneca from GBX 7,800 ($101.92) to GBX 8,000 ($104.53) and gave the company an overweight rating in a report on Friday, September 6th. Jefferies Financial Group reaffirmed a neutral rating on shares of AstraZeneca in a report on Thursday, August 29th. UBS Group reissued a sell rating and set a GBX 5,700 ($74.48) price objective on shares of AstraZeneca in a report on Tuesday, September 10th. Finally, Bryan, Garnier & Co reissued a neutral rating on shares of AstraZeneca in a report on Wednesday, July 3rd. Three research analysts have rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company’s stock. AstraZeneca currently has a consensus rating of Hold and a consensus target price of GBX 7,050 ($92.12).
AZN opened at GBX 6,847.69 ($89.48) on Wednesday. The firm has a market capitalization of $89.83 billion and a P/E ratio of 40.00. The stock’s 50 day moving average price is GBX 7,133.74 and its two-hundred day moving average price is GBX 6,387.83. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 144.48. AstraZeneca has a 12-month low of GBX 5,312 ($69.41) and a 12-month high of GBX 7,583 ($99.09).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: What is a closed-end mutual fund (CEF)?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.